DCR COMP1
Alternative Names: DCR-COMP-1Latest Information Update: 31 Jan 2022
At a glance
- Originator Dicerna Pharmaceuticals
- Developer Alexion AstraZeneca Rare Disease; Dicerna Pharmaceuticals
- Class Hepatoprotectants; Small interfering RNA
- Mechanism of Action Complement activation inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver disorders
Most Recent Events
- 31 Jan 2022 Dicerna Pharmaceutical enter into R&D agreement with Alexion AstraZeneca Rare Disease for the development of RNA interference (RNAi) therapies
- 20 Jan 2022 Alexion Pharmaceuticals was acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease .
- 20 Jan 2022 Dicerna Pharmaceuticals was acquired by Novo Nordisk